Literature DB >> 2574128

A rapid protocol for the purification of mitochondrial DNA suitable for studying restriction fragment length polymorphisms.

C Welter1, S Dooley, N Blin.   

Abstract

When analyzing mitochondrial DNA (mtDNA) from various normal and malignant human tissues, it became necessary to enhance mtDNA isolation for improved yields and quality. The method described here consists of rapid and simple-to-perform steps, avoiding complicated instrumentation. It was designed for preparation of undegraded mtDNA and is highly useful when limited amounts of tissues, cells and unique biopsies of tumors (fresh or frozen) are available. The resulting mtDNA is sufficiently pure for restriction analysis, subcloning, labeling and various types of hybridization. Using Sau3A and MspI, restriction analysis revealed new restriction-fragment length polymorphisms for Caucasians, independent of the DNA source, and hence excluding tissue-specific DNA modifications.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2574128     DOI: 10.1016/0378-1119(89)90415-0

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  4 in total

1.  Multi-copy nuclear pseudogenes of mitochondrial DNA reveal recent acute genetic changes in the human genome.

Authors:  G Hu; W G Thilly
Journal:  Curr Genet       Date:  1995-10       Impact factor: 3.886

2.  Nuclear complementation restores mtDNA levels in cultured cells from a patient with mtDNA depletion.

Authors:  A G Bodnar; J M Cooper; I J Holt; J V Leonard; A H Schapira
Journal:  Am J Hum Genet       Date:  1993-09       Impact factor: 11.025

3.  Respiratory-deficient human fibroblasts exhibiting defective mitochondrial DNA replication.

Authors:  A G Bodnar; J M Cooper; J V Leonard; A H Schapira
Journal:  Biochem J       Date:  1995-02-01       Impact factor: 3.857

4.  Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells.

Authors:  L Cui; S Yoon; R F Schinazi; J P Sommadossi
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.